ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1585

Suprascapular Nerve Block for the Treatment of Adhesive Capsulitis

Ernst Shanahan1, Elizabeth Briggs1, Tiffany Gill2, Catherine Hill3 and Tim Morris4, 1SA Health, Adelaide, Australia, 2University of Adelaide, Adelaide, Australia, 3Queen Elizabeth Hospital, Woodville, Australia, 4Flinders University, Adelaide, Australia

Meeting: ACR Convergence 2021

Keywords: clinical trial, Randomized Trial, shoulder disorders

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: To investigate the value of suprascapular nerve block (SSNB) as a treatment option for adhesive capsulitis.

Methods: Patients with adhesive capsulitis confirmed by a rheumatologist were invited to participate in the study. A randomised, double blind placebo controlled trial of standard therapy plus placebo versus standard therapy plus SSNB was performed. Standard therapy comprised an intra-articular glenohumeral joint injection of 20 mg of triamcenolone at time zero, plus a physiotherapist supervised exercise program. Patients received either a SSNB (10 mls of 0.5% bupivacaine and 40 mg of depomedrol) or placebo (3 mls of subcutaneous normal saline) injection at time zero and then at 3 monthly intervals until resolution. Resolution was defined as a return to full range of movement and a reduction of pain scores to normal, or recovery to the satisfaction of the patient. Pain, disability, range of movement and patient perceived rate of recovery scores were measured at 12 weekly intervals in the two groups.

Results: 54 patients (19 male, 35 female, mean age 54 years (range 32-72) participated. 27 patients received standard therapy plus the SSNB and 27 patients received standard therapy plus a placebo. 4 patients withdrew during the course of the study (all in the placebo group). The mean time to resolution of the symptoms was 5,4 months (CI 4,4-6.3) in the active group versus 11.2 months (CI 9.3-13.0) in the placebo group. Pain, disability, patient perceived rate of recovery and range of movement scores were significantly better in the actively treated group compared with the placebo group at all time intervals. The was one presycopal episode in the actively treated group but no other significant complications.

Conclusion: SSNB is highly effective in reducing the duration of frozen shoulder. It reduces pain significantly and is associated with high levels of patient satisfaction with recovery. It is safe and can be recommended as a useful adjunct therapy.

Survival analysis – Kaplan Meier curve, demonstrates the difference in time to resolution in the two groups.


Disclosures: E. Shanahan, None; E. Briggs, None; T. Gill, None; C. Hill, None; T. Morris, None.

To cite this abstract in AMA style:

Shanahan E, Briggs E, Gill T, Hill C, Morris T. Suprascapular Nerve Block for the Treatment of Adhesive Capsulitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/suprascapular-nerve-block-for-the-treatment-of-adhesive-capsulitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suprascapular-nerve-block-for-the-treatment-of-adhesive-capsulitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology